Literature DB >> 20186023

RBM5 as a putative tumor suppressor gene for lung cancer.

Leslie C Sutherland1, Ke Wang, Andrew G Robinson.   

Abstract

RBM5 is one member of a group of structurally related genes that includes RBM6 and RBM10. RBM10 maps to Xp11.23, and one allele is inactivated as a result of X chromosome inactivation. Both RBM5 and RBM6 map to 3p21.3, a tumor suppressor region that experiences loss of heterozygosity in the majority of lung cancers. Overexpression of RBM5, which encodes an RNA-binding protein involved in the regulation of alternative splicing and retards ascites associated tumor growth in immunocompromised mice, a phenomenon that may be related to an associated ability to modulate apoptosis. As part of our quest to gain a better understanding of how the proapoptotic activity of RBM5 might contribute to tumor suppressor function, we reviewed all the literature relating to RBM5 expression, with a focus on lung cancer. On the basis of the existing data, we suggest that-to more thoroughly assess the potential involvement of RBM5 as a lung cancer regulatory protein-more research is required regarding (a) the expression of not only full-length RBM5 but all of the alternate variants associated with the locus, in relation to histologic subtype and smoking history, and (b) the mutation status of various genes within the transforming growth factor-alpha signaling pathway, which may function to either directly or indirectly regulate RBM5 activity in RBM5-retaining lung cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186023     DOI: 10.1097/JTO.0b013e3181c6e330

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  32 in total

Review 1.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

2.  Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Authors:  David R Jones; Christopher A Moskaluk; Heidi H Gillenwater; Gina R Petroni; Sandra G Burks; Jennifer Philips; Patrice K Rehm; Juan Olazagasti; Benjamin D Kozower; Yongde Bao
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

3.  Nuclear Magnetic Resonance Structure of a Novel Globular Domain in RBM10 Containing OCRE, the Octamer Repeat Sequence Motif.

Authors:  Bryan T Martin; Pedro Serrano; Michael Geralt; Kurt Wüthrich
Journal:  Structure       Date:  2015-12-17       Impact factor: 5.006

Review 4.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

5.  Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.

Authors:  Runjun D Kumar; Adam C Searleman; S Joshua Swamidass; Obi L Griffith; Ron Bose
Journal:  Bioinformatics       Date:  2015-07-25       Impact factor: 6.937

6.  Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

Authors:  Jian Hong; Yunfei Yuan; Jianping Wang; Yadi Liao; Ruhai Zou; Chuanlong Zhu; Binkui Li; Yi Liang; Pinzhu Huang; Zongwei Wang; Wenyu Lin; Yixin Zeng; Jia Le Dai; Raymond T Chung
Journal:  Cancer Res       Date:  2014-01-29       Impact factor: 12.701

Review 7.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

8.  LncRNA RBM5-AS1 Promotes Osteosarcoma Cell Proliferation, Migration, and Invasion.

Authors:  Biyong Deng; Runsang Pan; Xin Ou; Taizhe Wang; Weiguo Wang; Yingjie Nie; Houping Chen
Journal:  Biomed Res Int       Date:  2021-03-15       Impact factor: 3.411

9.  Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.

Authors:  Hong Liang; Jie Zhang; Chen Shao; Lijing Zhao; Wei Xu; Leslie C Sutherland; Ke Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-04-26

10.  Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features.

Authors:  Jie Peng; Ali Kord Valeshabad; Qingfu Li; Yuan Wang
Journal:  Oncol Lett       Date:  2012-12-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.